Preview

Rational Pharmacotherapy in Cardiology

Advanced search

SECONDARY PHARMACOLOGICAL PREVENTION OF CARDIOVASCULAR DISEASES: OUR ABILITY IN CLINICAL PRACTICE

https://doi.org/10.20996/1819-6446-2012-8-6-788-797

Full Text:

Abstract

The most pressing issues of the secondary drug prevention of the most common cardiovascular diseases are focused. These are arterial hypertension, stable ischemic heart disease, chronic
heart failure.

About the Authors

E. V. Filippov
Ryazan State Medical University named after academician I.P . Pavlov
Russian Federation


S. S. Yakushin
Ryazan State Medical University named after academician I.P . Pavlov
Russian Federation


References

1. Yusuf S., Islam S., Chow C.K. et al. Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey. Lancet 2011; 378(9798):1231–43.

2. Russian statistical year 2011: Statistical Yearbook. Moscow: Rosstat; 2011. Russian (Российский статистический ежегодник 2011: Статистический сборник. М.: Росстат; 2011).

3. Oganov R.G., Shal'nova S.A., Kalinina A.M. Prevention of cardiovascular disease: a guide. Moscow: GEOTAR-Media; 2009. Russian (Оганов Р.Г., Шальнова С.А., Калинина А.М. Профилактика сердечно-сосудистых заболеваний: руководство. М.: ГЭОТАР-Медиа; 2009).

4. Yakushin S.S., Filippov E.V. Prevention of cardiovascular disease: a course on healthy lifestyle. Vrach 2011; 9(21):2–7. Russian (Якушин С.С., Филиппов Е.В. Профилактика сердечно-сосудистых заболеваний: курс на здоровый образ жизни. Врач 2011; 9(21):2–7).

5. National guidelines for cardiovascular prevention. Kardiovaskuljarnaja Terapija i Profilaktika 2011; 10(6) suppl 2: 1–64. Russian (Национальные рекомендации по кардиоваскулярной профилактике. Кардиоваскулярная Терапия и Профилактика 2011;10(6) Приложение 2: 1–64.

6. Remuzzi G., Ruggenenti P. Overview of randomised trials of ACE inhibitors. Lancet 2006; 368(9535):555–556.

7. Yusuf S., Sleight P., Pogue J. et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on death from cardiovascular causes, myocardial infarction, and stroke in high-risk patients. The Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. N Engl J Med 2000; 342(3):145–53.

8. Braunwald E., Domanski M.J., Fowler S.E. et al: Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med 2004; 351(20):2058–68.

9. Elliott W.J., Jonsson M.C., Black H.R.: Management of hypertension: is it the pressure or the drug? Circulation 2006; 113:2754–2774.

10. Yusuf S., Teo K.K., Pogue J. et al. Telmisartan, ramipril or both in patients at high risk for vascular events. N Engl J Med 2008; 358(15):1547–59.

11. van Vark L.C., Bertrand M., Akkerhuis K.M. et al. Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: A meta-analysis of randomized clinical trials of renin-angiotensin-aldosterone system inhibitors involving 158 998 patients. Eur Heart J 2012; 33(16):2088–97.

12. Yusuf S., Teo K., Anderson C. et al. Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators: Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet 2008; 372(9644):1174–83.

13. Yusuf S., Diener H.C., Sacco R.L. et al: Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med 2008; 359(12):1225–37.

14. Dahlöf B., Devereux R., de Faire U. et al. The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension study: rationale, design, and methods. Am J Hypertens 1997;10 (7 Pt 1) :705–13.

15. Schrader J., Lüders S., Kulschewski A. et al. Morbidity and mortality after stroke, eprosartan compared with nitrendipine for secondary prevention. Stroke 2005; 36(6):1218–26.

16. Kasanuki H., Hagiwara N., Hosoda S. et al. Angiotensin II receptor blocker-based vs. non-angiotensin II receptor blocker-based therapy in patients with angiographically documented coronary artery disease and hypertension: the Heart Institute of Japan Candesartan Randomized Trial for Evaluation in Coronary Artery Disease (HIJ-CREATE). Eur Heart J 2009; 30(10):1203–12.

17. Suzuki H., Kanno Y. Effects of candesartan on cardiovascular outcomes in Japanese hypertensive patients. Hypertens Res 2005; 28(4):307–14.

18. Mann J.E., Schmieder R.E., McQueen E.F. et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 2008; 372(9638):547–53.

19. Staessen J.A., Wang J.G., Thijs L. Cardiovascular protection and blood pressure reduction: a meta-analysis. Lancet 2001; 358(9290):1305–15.

20. Verdecchia P., Reboldi G., Angeli F. et al. Angiotensin-converting enzyme inhibitors and calcium channel blockers for coronary heart disease and stroke prevention. Hypertension 2005; 46(2):386–92.

21. Turnbull F. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003; 362(9395):1527–35.

22. Dahlöf B., Sever P.S., Poulter N.R. et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366(9489):895–906.

23. Collins R., Peto R., MacMahon S. et al. Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990; 335(8693):827–38.

24. Elliott W.J., Meier P.M. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 2007; 369(9557):201–7.

25. Bangalore S., Messerli F.H., Kostis J.B., Pepine C.J. Cardiovascular protection using beta-blockers: a critical review of the evidence. J Am Coll Cardiol 2007; 50(7):563–72.

26. NICE clinical guideline 127. Hypertension: clinical management of primary hypertension in adults. Available at: http://publications.nice.org.uk/hypertension-cg127. Date of access: 14.05.2012.

27. McMurray J.J., Adamopoulos S., Anker S.D. et al. Acute and Chronic Heart Failure 2012. ESC Clinical Practice Guidelines. Eur Heart J 2012:33;1787–1847.

28. Jamerson K., Weber M.A., Bakris G.L. et al: Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008; 359(23):2417–28.

29. Blumenthal R.S., Foody J.A., Wong N.D. et al. Preventive cardiology: A Companion to Braunwald's Heart Disease: 1nd ed. Philadelphia, PA: Elsevier/Saunders; 2011.

30. The top 10 causes of death. Fact sheet of WHO №310. June 2011. Available at: http://www.who.int/me-diacentre/factsheets/fs310/ru/index.html. Date of access: 14.05.2012.

31. Roger V.L., Go A.S., Lloyd-Jones D.M. et al. AHA Statistical Update. Heart Disease and Stroke Statistics—2012 Update. A Report From the American Heart Association. Circulation 2012; 125(1):e2– e220.

32. National guidelines for the diagnosis and treatment of stable angina. Kardiovaskuljarnaja Terapija i Pro-filaktika 2008; 7(6) suppl 4: 1–45. Russian (Национальные рекомендации по диагностике и лечению стабильной стенокардии. Кардиоваскулярная Терапия и Профилактика 2008; 7(6) При-ложение 4: 1–45.

33. Antithrombotic Trialists' Collaboration: Collaborative meta-analysis of randomised trials of an-tiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324(7329):71–86.

34. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Lancet 1988; 2(8607):349–60.

35. Hamm C.W., Bassand J.P., Agewall S. et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 2011; 32:2999– 3054.

36. Mehta S.R., Tanguay J.F., Eikelboom J.W. et al. Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. Lancet 2010; 376(9748):1233–43.

37. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 1996; 348(9038):1329–39.

38. Sarasin F.P., Gaspoz J.M., Bounameaux H. Cost-effectiveness of new antiplatelet regimens used as secondary prevention of stroke or transient ischemic attack. Arch Intern Med 2000; 160(18):2773–8.

39. Bhatt D.L., Fox K.A., Hacke W. et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006; 354(16):1706–17.

40. Vandvik P.O., Lincoff A.M., Gore J.M. et al. Primary and Secondary Prevention of Cardiovascular Disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. CHEST 2012; 141 (2 suppl): e637S–e668S.

41. The draft of National Guidelines on the efficacy and safety of drug therapy for primary and secondary prevention of cardiovascular disease. http://scardio.ru/recommendations/approved00349/default.asp. Date of access: 14.05.2012. Russian (Национальные рекомендации по эффективности и безопасности лекарственной терапии при первичной и вторичной профилактике сердечно-сосудистых заболеваний. Проект рекомендаций. http://scardio.ru/recommendations/approved00349/default.asp. Дата доступа: 14.05.2012).

42. Bonow R.O., Mann D.L., Zipes D.P., Libby P. eds. Braunwald's heart disease: a textbook of cardiovascular medicine: 9th ed. Philadelphia, PA: Saunders Elsevier; 2011.

43. Phillips K.A., Shlipak M.G., Coxson P. et al. Health and economic benefits of increased beta-blocker use following myocardial infarction. JAMA 2000; 284(21):2748–54.

44. Tokmakova M., Solomon S.D. Inhibiting the renin-angiotensin system in myocardial infarction and heart failure: Lessons from SAVE, VALIANT and CHARM, and other clinical trials. Curr Opin Cardiol 2006; 21(4):268–72.

45. Baker W.L., Coleman C.I., Kluger J. et al. Systematic review: Comparative effectiveness of angiotensin-converting enzyme inhibitors or angiotensin II-receptor blockers for ischemic heart disease. Ann Intern Med 2009; 151(12):861–71.

46. Cram J., Jespersen J. et al. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344(8934):1383–9.

47. Arnold S.V., Spertus J.A., Tang F. et al: Statin use in outpatients with obstructive coronary artery disease. Circulation 2011; 124(22):2405–10.

48. Sever P.S., Chang C.L., Gupta A.K., et al. The Anglo-Scandinavian Cardiac Outcomes Trial: 11-year mortality follow-up of the lipid-lowering arm in the UK. Eur Heart J 2011; 32(20):2525–32.

49. Baigent C., Blackwell L., Emberson J. et al. Safety of statin therapy: meta-analysis of data on cancer from 170,000 participants in 26 randomised trials. Lancet 2010; 376(9753):1670–81.

50. Mihaylova B., Briggs A., Armitage J. et al: Lifetime cost effectiveness of simvastatin in a range of risk groups and age groups derived from a randomised trial of 20,536 people. BMJ 2006; 333(7579):1145.

51. Gutierrez J., Ramirez G., Rundek T., Sacco R.L. Statin therapy in the prevention of recurrent cardiovascular events. A sex-based meta-analysis. Arch Intern Med 2012; 172(12):909–19.

52. Floyd J.S., Keckbert S.R., Weiss S.R. et al. Use of administrative data to estimate the incidence of statin-related rhabdomyolysis. JAMA 2012; 307(15):1580–2.

53. Egan A., Colman E. Weighing the Benefits of High-Dose Simvastatin against the Risk of Myopathy. N Engl J Med 2011; 365(4):285–7.

54. National guidelines on the diagnosis and treatment of chronic heart failure. Serdechnaja Nedostatochnost' 2010; 11(57):3–62. Russian (Национальные рекомендации по диагностике и лечению ХСН (третий пересмотр). Сердечная Недостаточность 2010; 11(57): 3–62).

55. Largent J., Bernstein L. et al. Hypertension, antihypertensive medication use, and breast cancer risk in the California Teachers Study cohort. Cancer Causes Control 2010; 21(10):1615–24.

56. Cosína J., Díezb J. et al. Torasemide in chronic heart failure: results of the TORIC study. Eur J Heart Fail 2002; 4(4):507–13.

57. The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997; 336(8):525–33.

58. Hood W.B., Dans A.L., Guyatt G.H. et al. Digitalis for treatment of congestive heart failure in patients in sinus rhythm: a systematic review and meta-analysis. J Card Fail 2004; 10(2):155–64.

59. Swedberg K., Komajda M., Bohm M. et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 2010; 376(9744):875–85.

60. Kromhout D., Giltay E.J., Geleijnse J.M. et al. N-3 Fatty Acids and Cardiovascular Events after Myocardial Infarction. N Engl J Med 2010; 363(21):2015–26.

61. Bosch J., Gerstein H.C., Dagenais G.R. et al. N-3 Fatty Acids and Cardiovascular Outcomes in Patients with Dysglycemia. N Engl J Med 2012; 367(4):309–18.

62. Sidik N.P., Solomon S.D., Latini R. et al. Effect of aliskiren in patients with heart failure according to background dose of ACE inhibitor: a retrospective analysis of the Aliskiren Observation of Heart Failure Treatment (ALOFT) trial. Cardiovasc Drugs Ther 2011; 25(4):315–21.

63. Konstam M.A., Gheorghiade M., Burnett J.C. et al. Effects of Oral Tolvaptan in Patients Hospitalized for Worsening Heart Failure. The EVEREST Outcome Trial. JAMA 2007; 297(12):1319–31.

64. Evaluating the Effectiveness of Sildenafil at Improving Health Outcomes and Exercise Ability in People With Diastolic Heart Failure (The RELAX Study). http://clinicaltrials.gov/ct2/show/NCT00763867. Date of access: 19.11.2012.

65. Fonarow G.C., Albert N.M., Curtis A.B. et al. Incremental reduction in the risk of death associated with use of guideline-recommended therapies in patients with heart failure: a nested case-control analysis of IMPROVE HF. J Am Heart Assoc 2012; 1(1):16–26.


For citation:


Filippov E.V., Yakushin S.S. SECONDARY PHARMACOLOGICAL PREVENTION OF CARDIOVASCULAR DISEASES: OUR ABILITY IN CLINICAL PRACTICE. Rational Pharmacotherapy in Cardiology. 2012;8(6):788-797. (In Russ.) https://doi.org/10.20996/1819-6446-2012-8-6-788-797

Views: 481


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)